caffeic acid has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, L; Liu, J; Wang, Q; Wu, Q; Yang, Z; Zhang, L; Zhang, Y | 1 |
| Ahmed, E; Alshareef, DM; El-Kherbetawy, MK; ElSayed, MH; Elsherbiny, NM; Mehanna, ET; Moustafa, YM; Zaitone, SA | 1 |
2 other study(ies) available for caffeic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Autophagy; Behavior, Animal; Brain; Caffeic Acids; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Gait; Humans; Male; MAP Kinase Kinase 4; Mice, Transgenic; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2 | 2019 |
Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Apoptosis; Behavior, Animal; Caffeic Acids; CD11b Antigen; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Inflammation Mediators; Locomotion; Male; Mice; Motor Activity; Neuroprotective Agents; NF-kappa B; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |